ArticleScientific reports2025
ViViMZheimer a slice based end to end model for Alzheimer's disease diagnosis from 3D MRI.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Slice-based models have been widely applied in Alzheimer's disease (AD) identification tasks due to their reduced parameter count and fast inference speed. However, existing slice-based models require additional slice extraction steps and cannot achieve an end-to-end process from MRI to diagnostic results. Moreover, they often rely on Transformer architectures to model inter-slice dependencies, which suffer from quadratic computational complexity. To address these limitations, we propose ViViMZheimer, a slice-based end-to-end model that directly processes 3D MRI data and generates diagnostic predictions. ViViMZheimer integrates a ViViT-inspired spatial encoder with a Mamba-based temporal modeling mechanism, maintaining linear computational complexity while effectively capturing inter-slice dependencies along three spatial orientations. Additionally, a lightweight spatial attention module emphasizes lesion-relevant brain regions, and a gated bottleneck convolution refines key features in later stages of the model. We evaluated ViViMZheimer on the ADNI dataset, where it achieved accuracies of 98.17%, 82.21%, and 83.15% in distinguishing AD vs. cognitively normal (CN), AD vs. mild cognitive impairment (MCI), and CN vs. MCI, respectively. These results demonstrate that ViViMZheimer provides an effective and computationally efficient solution for automated Alzheimer's disease diagnosis from 3D MRI scans.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.